Academic Geriatric Medicine, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
Cochrane Database Syst Rev. 2021 Nov 26;11(11):CD013307. doi: 10.1002/14651858.CD013307.pub3.
Delirium is an acute neuropsychological disorder that is common in hospitalised patients. It can be distressing to patients and carers and it is associated with serious adverse outcomes. Treatment options for established delirium are limited and so prevention of delirium is desirable. Non-pharmacological interventions are thought to be important in delirium prevention. OBJECTIVES: To assess the effectiveness of non-pharmacological interventions designed to prevent delirium in hospitalised patients outside intensive care units (ICU).
We searched ALOIS, the specialised register of the Cochrane Dementia and Cognitive Improvement Group, with additional searches conducted in MEDLINE, Embase, PsycINFO, CINAHL, LILACS, Web of Science Core Collection, ClinicalTrials.gov and the World Health Organization Portal/ICTRP to 16 September 2020. There were no language or date restrictions applied to the electronic searches, and no methodological filters were used to restrict the search.
We included randomised controlled trials (RCTs) of single and multicomponent non-pharmacological interventions for preventing delirium in hospitalised adults cared for outside intensive care or high dependency settings. We only included non-pharmacological interventions which were designed and implemented to prevent delirium. DATA COLLECTION AND ANALYSIS: Two review authors independently examined titles and abstracts identified by the search for eligibility and extracted data from full-text articles. Any disagreements on eligibility and inclusion were resolved by consensus. We used standard Cochrane methodological procedures. The primary outcomes were: incidence of delirium; inpatient and later mortality; and new diagnosis of dementia. We included secondary and adverse outcomes as pre-specified in the review protocol. We used risk ratios (RRs) as measures of treatment effect for dichotomous outcomes and between-group mean differences for continuous outcomes. The certainty of the evidence was assessed using GRADE. A complementary exploratory analysis was undertaker using a Bayesian component network meta-analysis fixed-effect model to evaluate the comparative effectiveness of the individual components of multicomponent interventions and describe which components were most strongly associated with reducing the incidence of delirium.
We included 22 RCTs that recruited a total of 5718 adult participants. Fourteen trials compared a multicomponent delirium prevention intervention with usual care. Two trials compared liberal and restrictive blood transfusion thresholds. The remaining six trials each investigated a different non-pharmacological intervention. Incidence of delirium was reported in all studies. Using the Cochrane risk of bias tool, we identified risks of bias in all included trials. All were at high risk of performance bias as participants and personnel were not blinded to the interventions. Nine trials were at high risk of detection bias due to lack of blinding of outcome assessors and three more were at unclear risk in this domain. Pooled data showed that multi-component non-pharmacological interventions probably reduce the incidence of delirium compared to usual care (10.5% incidence in the intervention group, compared to 18.4% in the control group, risk ratio (RR) 0.57, 95% confidence interval (CI) 0.46 to 0.71, I = 39%; 14 studies; 3693 participants; moderate-certainty evidence, downgraded due to risk of bias). There may be little or no effect of multicomponent interventions on inpatient mortality compared to usual care (5.2% in the intervention group, compared to 4.5% in the control group, RR 1.17, 95% CI 0.79 to 1.74, I = 15%; 10 studies; 2640 participants; low-certainty evidence downgraded due to inconsistency and imprecision). No studies of multicomponent interventions reported data on new diagnoses of dementia. Multicomponent interventions may result in a small reduction of around a day in the duration of a delirium episode (mean difference (MD) -0.93, 95% CI -2.01 to 0.14 days, I = 65%; 351 participants; low-certainty evidence downgraded due to risk of bias and imprecision). The evidence is very uncertain about the effect of multicomponent interventions on delirium severity (standardised mean difference (SMD) -0.49, 95% CI -1.13 to 0.14, I=64%; 147 participants; very low-certainty evidence downgraded due to risk of bias and serious imprecision). Multicomponent interventions may result in a reduction in hospital length of stay compared to usual care (MD -1.30 days, 95% CI -2.56 to -0.04 days, I=91%; 3351 participants; low-certainty evidence downgraded due to risk of bias and inconsistency), but little to no difference in new care home admission at the time of hospital discharge (RR 0.77, 95% CI 0.55 to 1.07; 536 participants; low-certainty evidence downgraded due to risk of bias and imprecision). Reporting of other adverse outcomes was limited. Our exploratory component network meta-analysis found that re-orientation (including use of familiar objects), cognitive stimulation and sleep hygiene were associated with reduced risk of incident delirium. Attention to nutrition and hydration, oxygenation, medication review, assessment of mood and bowel and bladder care were probably associated with a reduction in incident delirium but estimates included the possibility of no benefit or harm. Reducing sensory deprivation, identification of infection, mobilisation and pain control all had summary estimates that suggested potential increases in delirium incidence, but the uncertainty in the estimates was substantial. Evidence from two trials suggests that use of a liberal transfusion threshold over a restrictive transfusion threshold probably results in little to no difference in incident delirium (RR 0.92, 95% CI 0.62 to 1.36; I = 9%; 294 participants; moderate-certainty evidence downgraded due to risk of bias). Six other interventions were examined, but evidence for each was limited to single studies and we identified no evidence of delirium prevention. AUTHORS' CONCLUSIONS: There is moderate-certainty evidence regarding the benefit of multicomponent non-pharmacological interventions for the prevention of delirium in hospitalised adults, estimated to reduce incidence by 43% compared to usual care. We found no evidence of an effect on mortality. There is emerging evidence that these interventions may reduce hospital length of stay, with a trend towards reduced delirium duration, although the effect on delirium severity remains uncertain. Further research should focus on implementation and detailed analysis of the components of the interventions to support more effective, tailored practice recommendations.
谵妄是一种常见于住院患者的急性神经心理障碍。它会给患者和护理人员带来痛苦,并与严重的不良后果相关。对于已确诊的谵妄,治疗选择有限,因此预防谵妄是可取的。非药物干预被认为在预防谵妄方面很重要。
评估旨在预防非重症监护病房(ICU)住院患者谵妄的非药物干预措施的有效性。
我们检索了专门针对 Cochrane 痴呆和认知改善组的 ALOIS,此外还在 MEDLINE、Embase、PsycINFO、CINAHL、LILACS、Web of Science 核心合集、ClinicalTrials.gov 和世界卫生组织门户/ICTRP 进行了额外的检索,检索截至 2020 年 9 月 16 日。我们对电子检索没有设置语言或日期限制,也没有使用方法学过滤器来限制检索。
我们纳入了随机对照试验(RCTs),这些试验研究了单一和多成分非药物干预措施预防住院成人在重症监护或高依赖环境之外发生谵妄的效果。我们只纳入了旨在预防谵妄的非药物干预措施。
两名综述作者独立检查了搜索结果的标题和摘要,以确定其是否符合纳入标准,并从全文文章中提取数据。对是否符合纳入标准和纳入的任何分歧,我们都通过共识来解决。我们使用了标准的 Cochrane 方法学程序。主要结局指标包括:谵妄的发生率;住院和之后的死亡率;以及新诊断的痴呆。我们纳入了预先规定的次要结局和不良结局。我们使用风险比(RR)作为二分类结局的治疗效果指标,使用组间均值差作为连续结局的治疗效果指标。使用 GRADE 评估证据的确定性。我们还进行了一项补充的探索性分析,使用贝叶斯组件网络荟萃分析固定效应模型来评估多成分干预措施中各个成分对降低谵妄发生率的相对有效性,并描述哪些成分与降低谵妄发生率的关联最强。
我们纳入了 22 项 RCT,共纳入了 5718 名成年参与者。14 项试验比较了多成分谵妄预防干预与常规护理。两项试验比较了宽松和严格的输血阈值。其余 6 项试验各自研究了一种不同的非药物干预措施。所有研究均报告了谵妄的发生率。使用 Cochrane 偏倚风险工具,我们发现所有纳入的试验都存在偏倚风险。所有试验均存在高偏倚风险,因为参与者和医务人员对干预措施均未设盲。由于结局评估人员未设盲,有 9 项试验存在高检测偏倚风险,另有 3 项试验在该领域的偏倚风险不明确。汇总数据表明,多成分非药物干预措施可能与常规护理相比降低谵妄的发生率(干预组的发生率为 10.5%,对照组为 18.4%,RR 0.57,95%置信区间(CI)0.46 至 0.71,I = 39%;14 项研究;3693 名参与者;中等确定性证据,因偏倚而降级)。与常规护理相比,多成分干预措施可能对住院期间的死亡率几乎没有或没有影响(干预组的死亡率为 5.2%,对照组的死亡率为 4.5%,RR 1.17,95%CI 0.79 至 1.74,I = 15%;10 项研究;2640 名参与者;低确定性证据,因不一致和不精确而降级)。没有研究报告多成分干预措施对新诊断痴呆的影响。多成分干预措施可能会使谵妄发作的持续时间缩短约一天(平均差值(MD)-0.93,95%CI-2.01 至 0.14 天,I = 65%;351 名参与者;低确定性证据,因偏倚和不精确而降级)。与常规护理相比,多成分干预措施对谵妄严重程度的影响证据非常不确定(标准化均数差值(SMD)-0.49,95%CI-1.13 至 0.14,I = 64%;147 名参与者;非常低确定性证据,因偏倚和严重不精确而降级)。与常规护理相比,多成分干预措施可能会减少住院时间(MD-1.30 天,95%CI-2.56 至-0.04 天,I = 91%;3351 名参与者;低确定性证据,因偏倚和不一致而降级),但在出院时新入住护理院的可能性几乎没有差异(RR 0.77,95%CI 0.55 至 1.07;536 名参与者;低确定性证据,因偏倚和不精确而降级)。不良结局的报告有限。我们的探索性成分网络荟萃分析发现,定向(包括使用熟悉的物品)、认知刺激和睡眠卫生与降低谵妄风险有关。关注营养和水合作用、氧合作用、药物评估、情绪和肠膀胱护理可能与降低谵妄风险有关,但估计结果包括无益处或无危害的可能性。减少感官剥夺、识别感染、活动和疼痛控制都有汇总估计值表明可能增加谵妄的发生率,但估计值的不确定性很大。两项试验的证据表明,与限制性输血阈值相比,使用宽松性输血阈值可能对谵妄发生率几乎没有或没有影响(RR 0.92,95%CI 0.62 至 1.36;I = 9%;294 名参与者;中等确定性证据,因偏倚而降级)。另外 6 项干预措施进行了检验,但每项干预措施的证据仅限于单项研究,我们没有发现预防谵妄的证据。
有中等确定性证据表明,多成分非药物干预措施对预防住院成人谵妄有效,与常规护理相比,可降低 43%的谵妄发生率。我们没有发现对死亡率有影响的证据。有新证据表明,这些干预措施可能会缩短住院时间,且有降低谵妄持续时间的趋势,但谵妄严重程度的影响仍不确定。未来的研究应重点关注实施和详细分析干预措施的组成部分,以支持更有效、更有针对性的实践建议。